We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Actividentity Corp (MM) | NASDAQ:ACTI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.24 | 0 | 01:00:00 |
LUND, Sweden, April 28, 2016 (GLOBE NEWSWIRE) --
Laquinimod
Tasquinimod
ANYARA, Paquinimod (57-57) and SILC (ISI)
Financial summary
MSEK | Jan. - Mar. | Full Year | |||
2016 | 2015 | 2015 | |||
Net sales | 3.9 | 2.9 | 16.3 | ||
Operating loss | -16.1 | -57.4 | -177.9 | ||
Loss for the period | -16.8 | -58.0 | -193.5 | ||
Loss per share, before and after dilution (SEK) | -0.19 | -0.64 | -2.15 | ||
Cash and cash equivalents (at the end of the period) | 76.5 | 270.5 | 103.6 |
For further information, please contact: Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund, Sweden Tel: +46 (0)46 19 20 00 Fax: +46 (0)46 19 11 05 The report is also available at www.activebiotech.com.
Active Biotech AB (publ) Interim report January - March 2016 http://hugin.info/1002/R/2007548/742184.pdf
HUG#2007548
1 Year Actividentity Corp (MM) Chart |
1 Month Actividentity Corp (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions